KR20070120954A - 신혈관 형성-의존성 종양 치료용 약학적 제제 - Google Patents

신혈관 형성-의존성 종양 치료용 약학적 제제 Download PDF

Info

Publication number
KR20070120954A
KR20070120954A KR1020077021114A KR20077021114A KR20070120954A KR 20070120954 A KR20070120954 A KR 20070120954A KR 1020077021114 A KR1020077021114 A KR 1020077021114A KR 20077021114 A KR20077021114 A KR 20077021114A KR 20070120954 A KR20070120954 A KR 20070120954A
Authority
KR
South Korea
Prior art keywords
use according
neovascularization
tumor
oligodioxyribonucleotides
tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020077021114A
Other languages
English (en)
Korean (ko)
Inventor
마시모 이아코벨리
건터 아이스너
로라 아이리스 페로
Original Assignee
젠티엄 에스피에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT000336A external-priority patent/ITMI20050336A1/it
Application filed by 젠티엄 에스피에이 filed Critical 젠티엄 에스피에이
Publication of KR20070120954A publication Critical patent/KR20070120954A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020077021114A 2005-03-03 2006-02-27 신혈관 형성-의존성 종양 치료용 약학적 제제 Withdrawn KR20070120954A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ITMI2005A000336 2005-03-03
IT000336A ITMI20050336A1 (it) 2005-03-03 2005-03-03 Formulazione ad attivita' anti-tumorale
US73140405P 2005-10-28 2005-10-28
US60/731,404 2005-10-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020077023861A Division KR20070121001A (ko) 2005-03-03 2006-02-27 신혈관 형성-의존성 종양 치료용 약학적 제제

Publications (1)

Publication Number Publication Date
KR20070120954A true KR20070120954A (ko) 2007-12-26

Family

ID=36572331

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020077023861A Withdrawn KR20070121001A (ko) 2005-03-03 2006-02-27 신혈관 형성-의존성 종양 치료용 약학적 제제
KR1020077021114A Withdrawn KR20070120954A (ko) 2005-03-03 2006-02-27 신혈관 형성-의존성 종양 치료용 약학적 제제
KR1020077021110A Withdrawn KR20070120953A (ko) 2005-03-03 2006-02-27 항암활성을 갖는 제제

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020077023861A Withdrawn KR20070121001A (ko) 2005-03-03 2006-02-27 신혈관 형성-의존성 종양 치료용 약학적 제제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020077021110A Withdrawn KR20070120953A (ko) 2005-03-03 2006-02-27 항암활성을 갖는 제제

Country Status (9)

Country Link
US (2) US20080194506A1 (enExample)
EP (2) EP1853277A1 (enExample)
JP (2) JP2008531647A (enExample)
KR (3) KR20070121001A (enExample)
AU (2) AU2006222044A1 (enExample)
CA (2) CA2598613A1 (enExample)
IL (3) IL185182A0 (enExample)
MX (2) MX2007010754A (enExample)
WO (2) WO2006094917A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20031714A1 (it) 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
EP1982722A1 (en) * 2007-04-16 2008-10-22 Gentium S.p.A. Use of oligotide for the treatment of renal diseases
EP2103689A1 (en) * 2008-03-19 2009-09-23 Gentium S.p.A. Synthetic phosphodiester oligonucleotides and therapeutical uses thereof
US8187897B2 (en) 2008-08-19 2012-05-29 International Business Machines Corporation Fabricating product chips and die with a feature pattern that contains information relating to the product chip
DK2637672T3 (en) 2010-11-12 2018-10-22 Gentium S R L DEFIBROTID FOR USE IN PROPHYLAXY AND / OR TREATMENT OF GRAPHIC VERSUS HOST DISEASE (GVHD)
CN110079580B (zh) 2012-06-22 2022-12-06 真蒂奥姆责任有限公司 用于测定去纤维蛋白多核苷酸的生物活性的基于优球蛋白的方法
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
SG11202000952PA (en) 2017-08-03 2020-02-27 Jazz Pharmaceuticals Ireland Ltd Formulations comprising a nucleic acid in a high concentration
MX2020010689A (es) 2018-04-12 2021-01-20 Jazz Pharmaceuticals Inc Defibrotida para la prevencion y tratamiento del sindrome de liberacion de citocinas y la neurotoxicidad asociada con la inmunodeplecion.
US20220023533A1 (en) 2018-12-07 2022-01-27 Jazz Phrmaceticals Ireland Limited Subcutaneous delivery of high concentration formulations
US20230190783A1 (en) 2020-02-28 2023-06-22 Jazz Pharmaceuticals Ireland Limited Delivery of low viscosity formulations
TW202308659A (zh) 2021-05-06 2023-03-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 用於急性呼吸窘迫症候群之治療及預防的去纖維蛋白多核苷酸

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2154279A1 (de) * 1970-11-03 1972-05-25 Crinos Industria Farmaco Medikamente für das fibrinolytische System
IT1043823B (it) * 1970-11-03 1980-02-29 Prephar Procedimento per l estrazione di acidi nucleici da organi animali
US3899481A (en) * 1970-11-03 1975-08-12 Crinos Industria Farmaco Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs
IT1170214B (it) * 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per la cura delle arteriopatie periferiche
IT1206341B (it) * 1984-02-16 1989-04-14 Crinos Industria Farmaco Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio.
US4694134A (en) * 1985-05-28 1987-09-15 Ajax Magnethermic Corporation Apparatus for overheating edges of skelp for the production of compression welded pipe
US5223609A (en) * 1986-04-17 1993-06-29 Crinos Industria Farmacobiologica S.P.A. Process for obtaining chemically defined and reproducible polydeoxyribonucleotides
IT1190313B (it) * 1986-04-17 1988-02-16 Crinos Industria Farmaco Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante
US6699985B2 (en) * 1991-08-21 2004-03-02 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
US5977083A (en) * 1991-08-21 1999-11-02 Burcoglu; Arsinur Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
IT1252174B (it) * 1991-12-09 1995-06-05 Crinos Industria Farmaco Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento
US5578716A (en) * 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
AU754242B2 (en) * 1997-04-28 2002-11-07 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
JP2002512508A (ja) * 1997-05-30 2002-04-23 マクギル・ユニヴァーシティ Ｄｎａメチルトランスフェラーゼゲノミック配列およびアンチセンスオリゴヌクレオチド
DE19740384A1 (de) * 1997-09-08 1999-03-11 Max Delbrueck Centrum Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN
US7514414B2 (en) * 2001-09-24 2009-04-07 The United States Of America As Represented By The Department Of Health And Human Services Suppressors of CpG oligonucleotides and methods of use
ITMI20031714A1 (it) * 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.

Also Published As

Publication number Publication date
CA2598072A1 (en) 2006-09-14
US20080194506A1 (en) 2008-08-14
AU2006222044A1 (en) 2006-09-14
EP1855697A2 (en) 2007-11-21
AU2006222045A1 (en) 2006-09-14
IL185182A0 (en) 2008-01-20
JP2008531647A (ja) 2008-08-14
JP2008531646A (ja) 2008-08-14
IL185258A0 (en) 2008-02-09
WO2006094917A3 (en) 2006-12-14
EP1853277A1 (en) 2007-11-14
KR20070120953A (ko) 2007-12-26
US20080194507A1 (en) 2008-08-14
JP5714203B2 (ja) 2015-05-07
CA2598613A1 (en) 2006-09-14
WO2006094916A1 (en) 2006-09-14
IL185258A (en) 2010-12-30
WO2006094917A2 (en) 2006-09-14
WO2006094917A8 (en) 2008-01-31
IL185181A0 (en) 2008-01-20
KR20070121001A (ko) 2007-12-26
MX2007010754A (es) 2007-11-07
MX2007010407A (es) 2007-10-17
AU2006222045B2 (en) 2011-10-20
CA2598072C (en) 2016-05-03

Similar Documents

Publication Publication Date Title
JP6902570B6 (ja) 修飾型ｒｎａ（ｍｏｄ−ｒｎａ）を使用する効率的なインビボタンパク質発現
KR20070120954A (ko) 신혈관 형성-의존성 종양 치료용 약학적 제제
PT1956093E (pt) Protease de clivagem do factor von willebrand (vwf)
Zhu et al. Blocking tumor-platelet crosstalk to prevent tumor metastasis via reprograming glycolysis using biomimetic membrane-hybridized liposomes
CN102119214A (zh) 适合于癌症治疗的包含体外扩增的t淋巴细胞和血管形成抑制剂的组合物
Hoda et al. Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy
Liu et al. G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice
Robl et al. Evaluation of F8-TNF-α in models of early and progressive metastatic osteosarcoma
Chen et al. p38gamma overexpression promotes renal cell carcinoma cell growth, proliferation and migration
KR102150239B1 (ko) Ｄｒｇ２ 억제제를 유효성분으로 포함하는 항암용 조성물
Ziche et al. Linomide blocks angiogenesis by breast carcinoma vascular endothelial growth factor transfectants
EP1867335B1 (en) Oligodeoxyribonucleotides combined with rapamycin for treating cancer
AU2007231651B2 (en) Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors
WO2014100565A1 (en) Methods and compositions relating to treatment of cancer
Cao et al. RETRACTED: Oroxylin a Inhibits the Protection of Bone Marrow Microenvironment on CML Cells Through CXCL12/CXCR4/P-gp Signaling Pathway
Chen et al. Comparison of tumor-derived total RNA and cell lysate on antitumor immune activity
Zhang et al. Biomimetic immortalized mesenchymal stem cell-based nanoparticles suppress orthotopic postsurgical glioma via CD73 targeting and chemotherapy
Huang et al. Flavonoids from Millettia Speciosa Champ Inhibit the Migration and Angiogenesis of Prostate Cancer Cells
US20220160812A1 (en) A pharmaceutically active substance
Rollin et al. P-109 Comparative expression of RECK, MMP-2, MMP-9 and VEGFgenes in non-small cell lung cancer
Nia et al. P-110 A novel biologic classification of non-small cell lung cancer
Ireland Understanding the role of the tumour microenvironment in chemoresistance and tumour progression
Ruggiero et al. 401 A new Golgi-based signalling cascade involved in tumoural cell invasion
JINGJING THE ROLE OF AUTOCRINE HUMAN GROWTH HORMONE IN COLORECTAL CANCER PROGRESSION
Zhao et al. CD44-specific targeted lipid nanoparticles enhance the anti-tumor efficacy of RNA therapeutics in cancer therapy

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070914

Patent event code: PA01051R01D

Comment text: International Patent Application

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20071017

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid